Revolution Medicines officer proposes $18.7M sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Revolution Medicines, Inc. (RVMD) officer Stephen Kelsey reported a proposed sale of 108,640 common shares, with an aggregate market value of $18,717,585.60 and an approximate sale date of November 16, 2026.
The notice says the shares were and will be received through stock-option exercises over the next three months. It lists August 17, 2026 as the plan adoption or instruction date, if relying on Rule 10b5-1. During the prior three months, Stephen Kelsey reported sales of 5,569 shares for gross proceeds of $1,109,554.38 on September 16, 2026, and 92,531 shares for gross proceeds of $18,724,768.18 on September 11, 2026; the latter is identified as a 10b5-1 sale.
Key Figures
Key Terms
stock options financial
Rule 10b5-1 regulatory
aggregate market value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.